ClinicalTrials.gg

Program

cysteamine-pantetheine disulfide

Also written as “TTI-0102”, “TTI-0102 (cysteamine-pantetheine disulfide)” and “TTI-0102: cysteamine-pantetheine disulfide”.

Its studies are mostly in Cystinosis · MELAS Syndrome · Leigh Disease · COVID-19, led by Thiogenesis Therapeutics.

Furthest: phase 2, since Jan 26, 20224 company-led studies, 2 open or runningNext primary completion: Dec 2026 (phase 2)

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
Thiogenesis Therapeutics42 open or runningphase 2since Jan 26, 2022Jan 26, 2022Dec 2026phase 2 · NCT07837726

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

  1. Jan 26, 2022First study: phase 2 study in COVID-19First studyNCT05212662
  2. Sep 29, 2024Phase 2 study in MELAS SyndromeNCT06644534 · 9 enrolled · France, Netherlands
  3. May 6, 2025Phase 2 study in Leigh DiseaseNCT06990984 · 18 planned
  4. Sep 13, 2026Phase 2 study in CystinosisNCT07837726 · 6 planned

Ahead

  1. Dec 2026Primary completion: phase 2 study in CystinosisNCT07837726
  2. Jun 2027Primary completion: phase 2 study in Leigh DiseaseNCT06990984

TargetBeta

Not stated by its company or a source we have read. Most early programs say nothing of it.

Studies

All 4 led by companies developing it, newest first. Each opens its study page.

StudyPhaseStatusPrimary completionSize
NCT07837726Cystinosis2Not yet recruitingDec 20266
NCT06990984Leigh Disease2Not yet recruitingJun 202718
NCT06644534MELAS Syndrome · France, Netherlands2CompletedJan 12, 20269
NCT05212662COVID-192WithdrawnSep 27, 20240

How it is read

Names in the registry

  • “TTI-0102”, 2 entries
  • “TTI-0102 (cysteamine-pantetheine disulfide)”, 1 entry
  • “TTI-0102: cysteamine-pantetheine disulfide”, 1 entry

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.
cysteamine-pantetheine disulfide (Thiogenesis Therapeutics): development program | ClinicalTrials.gg